{"transactions":[{"id":2465321,"issuer":{"id":132212,"kind":"organization","name":"Soliton, Inc.","symbol":"SOLY"},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-12-17T17:09:55.000Z","date":"2021-12-16","kind":"disposition_to_issuer","acquired":false,"shares":170808,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":12.88,"expiration_date":"2024-10-11","underlying":"Common Stock","underlying_shares":170808},"source":{"system":"sec-edgar","filing":"0001548187-21-000080","document":"wf-form4_163977897775621.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1548187/000154818721000080/wf-form4_163977897775621.xml","form_type":"4"}},{"id":2465320,"issuer":{"id":132212,"kind":"organization","name":"Soliton, Inc.","symbol":"SOLY"},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-12-17T17:09:55.000Z","date":"2021-12-16","kind":"disposition_to_issuer","acquired":false,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2024-06-19","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001548187-21-000080","document":"wf-form4_163977897775621.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1548187/000154818721000080/wf-form4_163977897775621.xml","form_type":"4"}},{"id":2465319,"issuer":{"id":132212,"kind":"organization","name":"Soliton, Inc.","symbol":"SOLY"},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-17T17:09:55.000Z","date":"2021-12-16","kind":"disposition_to_issuer","acquired":false,"shares":9214277,"price":22.6,"value":208242660.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the \"Merger Agreement\"), by and among Soliton, Inc. (the \"Company\"), AbbVie Inc. (\"AbbVie\") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie (\"Merger Sub\"), at the effective time of the merger of Merger Sub with and into the Company (the \"Merger\"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the \"Merger Consideration\"), without interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the \"Merger Agreement\"), by and among Soliton, Inc. (the \"Company\"), AbbVie Inc. (\"AbbVie\") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie (\"Merger Sub\"), at the effective time of the merger of Merger Sub with and into the Company (the \"Merger\"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the \"Merger Consideration\"), without interest."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001548187-21-000080","document":"wf-form4_163977897775621.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1548187/000154818721000080/wf-form4_163977897775621.xml","form_type":"4"}},{"id":3094869,"issuer":{"id":132212,"kind":"organization","name":"Soliton, Inc.","symbol":"SOLY"},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-01T20:30:53.000Z","date":"2020-06-30","kind":"purchase","acquired":true,"shares":120481,"price":8.3,"value":999992.3,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock  subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein."}],"balance_after":9214277,"source":{"system":"sec-edgar","filing":"0001548187-20-000086","document":"wf-form4_159364983717876.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1548187/000154818720000086/wf-form4_159364983717876.xml","form_type":"4"}},{"id":3393457,"issuer":{"id":132212,"kind":"organization","name":"Soliton, Inc.","symbol":"SOLY"},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"ten_percent_owner":true}}],"security":"Warrant (right to buy)","published_at":"2019-10-15T18:08:38.000Z","date":"2019-10-11","kind":"purchase","acquired":true,"shares":170808,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock and warrant was issued as part of a unit of securities consisting of (i) one share of the Issuer's common stock, and (ii) 1.1 of a warrant to purchase one share of common stock. The offering price of the units was $12.88 per unit."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein."}],"balance_after":420808,"derivative":{"exercise_price":12.88,"exercise_date":"2019-10-11","expiration_date":"2024-10-11","underlying":"Common Stock","underlying_shares":170808},"source":{"system":"sec-edgar","filing":"0001437749-19-020084","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1548187/000143774919020084/rdgdoc.xml","form_type":"4"}},{"id":3393456,"issuer":{"id":132212,"kind":"organization","name":"Soliton, Inc.","symbol":"SOLY"},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2019-10-15T18:08:38.000Z","date":"2019-10-11","kind":"purchase","acquired":true,"shares":155280,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock and warrant was issued as part of a unit of securities consisting of (i) one share of the Issuer's common stock, and (ii) 1.1 of a warrant to purchase one share of common stock. The offering price of the units was $12.88 per unit."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein."}],"balance_after":9093796,"source":{"system":"sec-edgar","filing":"0001437749-19-020084","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1548187/000143774919020084/rdgdoc.xml","form_type":"4"}},{"id":3483754,"issuer":{"id":132212,"kind":"organization","name":"Soliton, Inc.","symbol":"SOLY"},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"ten_percent_owner":true}}],"security":"Warrant (right to buy)","published_at":"2019-06-19T17:16:09.000Z","date":"2019-06-19","kind":"purchase","acquired":true,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock and warrant was issued as part of a unit of securities consisting of (i) one share of the Issuer's common stock, and (ii) 0.7 of a warrant to purchase one share of common stock. The offering price of the units was $14.00 per unit."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The warrant expires five years after the effective date of the resale registration statement registering the shares of common stock underlying the warrant, or when such shares may sold without restriction pursuant to Rule 144 of the Securities Act of 1933."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein."}],"balance_after":250000,"derivative":{"exercise_price":16,"exercise_date":"2019-06-19","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001437749-19-012300","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1548187/000143774919012300/rdgdoc.xml","form_type":"4"}},{"id":3483753,"issuer":{"id":132212,"kind":"organization","name":"Soliton, Inc.","symbol":"SOLY"},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2019-06-19T17:16:09.000Z","date":"2019-06-19","kind":"purchase","acquired":true,"shares":357143,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock and warrant was issued as part of a unit of securities consisting of (i) one share of the Issuer's common stock, and (ii) 0.7 of a warrant to purchase one share of common stock. The offering price of the units was $14.00 per unit."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein."}],"balance_after":8938516,"source":{"system":"sec-edgar","filing":"0001437749-19-012300","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1548187/000143774919012300/rdgdoc.xml","form_type":"4"}},{"id":4086186,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-01-29T21:19:55.000Z","date":"2018-01-29","kind":"exercise","acquired":false,"shares":821596,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":304576},"source":{"system":"sec-edgar","filing":"0001209191-18-005831","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919118005831/doc4.xml","form_type":"4"}},{"id":4086185,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-01-29T21:19:55.000Z","date":"2018-01-29","kind":"exercise","acquired":false,"shares":2351097,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":871583},"source":{"system":"sec-edgar","filing":"0001209191-18-005831","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919118005831/doc4.xml","form_type":"4"}},{"id":4086184,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-01-29T21:19:55.000Z","date":"2018-01-29","kind":"exercise","acquired":false,"shares":7150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2650},"source":{"system":"sec-edgar","filing":"0001209191-18-005831","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919118005831/doc4.xml","form_type":"4"}},{"id":4086183,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-01-29T21:19:55.000Z","date":"2018-01-29","kind":"exercise","acquired":true,"shares":304576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."}],"balance_after":2761663,"source":{"system":"sec-edgar","filing":"0001209191-18-005831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919118005831/doc4.xml","form_type":"4"}},{"id":4086182,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-01-29T21:19:55.000Z","date":"2018-01-29","kind":"exercise","acquired":true,"shares":871583,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."}],"balance_after":2457087,"source":{"system":"sec-edgar","filing":"0001209191-18-005831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919118005831/doc4.xml","form_type":"4"}},{"id":4086181,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-01-29T21:19:55.000Z","date":"2018-01-29","kind":"exercise","acquired":true,"shares":2650,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock."}],"balance_after":1585504,"source":{"system":"sec-edgar","filing":"0001209191-18-005831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919118005831/doc4.xml","form_type":"4"}},{"id":4086180,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-01-29T21:19:55.000Z","date":"2018-01-25","kind":"purchase","acquired":true,"shares":100000,"price":17,"value":1700000.0,"ownership":{"direct":true},"balance_after":1582854,"source":{"system":"sec-edgar","filing":"0001209191-18-005831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919118005831/doc4.xml","form_type":"4"}},{"id":4509761,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":132214,"kind":"organization","name":"Remeditex Ventures LLC","position":1,"cik":"0001627363","reported_name":"Remeditex Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-12-30T08:31:30.000Z","date":"2019-12-29","kind":"other","acquired":true,"shares":1309392,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. (\"Old Apollo\") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the \"Merger Agreement\"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock.  Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. (\"Old Apollo\") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the \"Merger Agreement\"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock.  Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by Remeditex Ventures, LLC.  John W. Creecy is the Chief Executive Officer and Director of Remeditex Ventures, LLC and may be deemed to be the beneficial owner of the securities held by Remeditex Ventures, LLC.  Mr. Creecy is a director of the Issuer and, accordingly, files separate Section 16 reports."}],"balance_after":1309392,"source":{"system":"sec-edgar","filing":"0001179110-16-033598","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000117911016033598/edgar.xml","form_type":"4"}}]}